Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

By clicking “Accept” you acknowledge and agree that neither ITGR nor third party provider Virtua Research, Inc. (“Virtua) is responsible, or accepts or assumes any responsibility or liability whatsoever for, the content, the data or the technical operation of the Linked Site. Further, by entering the External Site, you also acknowledge and agree that you completely and irrevocably waive any and all rights and claims against ITGR and Virtua and further acknowledge and agree that in no event shall ITGR or Virtua, its officers, employees, directors and agents be liable for any (i) indirect, consequential, incidental, special, compensatory or punitive damages, (ii) damages for loss of income, loss of business profits, business interruption, loss of data or business information, loss of or damage to property, (iii) claims of third parties, or (iv) other pecuniary loss, arising out of or related to this disclaimer or the External Site

By entering the External Site, you further acknowledge and agree that the disclaimer of warranties and limitations of liability set out in this disclaimer shall apply regardless of the causes, circumstances or form of action giving rise to the loss, damage, claim or liability, even if such loss, damage, claim or liability is based upon breach of contract (including, without limitation, a claim of fundamental breach or breach of a fundamental term), tort (including, without limitation, negligence), strict liability or any other legal or equitable theory, and even if ITGR and Virtua are advised of the possibility of the loss, damage, claim or liability. The waiver and release specifically includes, without limitation, any and all rights and claims pertaining to the processing of personal data, including but not limited to any rights under any applicable data protection statute(s).

If in any jurisdiction, any part of this disclaimer is held to be unenforceable by a court of competent jurisdiction, such part of this disclaimer shall be restricted or eliminated to the minimum extent and the remaining disclaimer shall otherwise remain in full force and effect.

Please note the information presented is deemed representative at the time of its original release. Changes in historical information may occur due to adjustments in accounting and reporting standards & procedures.

Non-GAAP Information

In addition to disclosing results determined in accordance with GAAP, ITGR may also disclose certain non-GAAP and pro forma non-GAAP results of operations, including certain ratios, operational and miscellaneous data, as well as net income, diluted earnings per share, operating expenses, and operating income that make certain adjustments or exclude certain charges and gains that are outlined in the schedules included in this website. Management believes that this non-GAAP and pro forma non-GAAP information provides investors with additional information to assess ITGR operating performance by making certain adjustments or excluding costs or gains and assists investors in comparing our operating performance to prior periods. Management uses this non-GAAP and pro forma non-GAAP information, along with GAAP information, in evaluating its historical operating performance. ITGR and Virtua also take no responsibility for third party pricing data provided for informational purposes and certain ratio results formulated from the provided third party pricing data.

The non-GAAP information is not prepared in accordance with GAAP and may not be comparable to non-GAAP information used by other companies. The non-GAAP information should not be viewed as a substitute for, or superior to, other data prepared in accordance with GAAP.

Integer Holdings Corporation Reports First Quarter 2017 Results

May 8, 2017

~ Company Reaffirms Full-Year Sales & Adjusted Diluted EPS Guidance ~

Note: A webcast of Integer’s conference call and accompanying presentation slides will be available at 5:00 p.m. EDT today at http://investor.integer.net.

FRISCO, Texas, May 08, 2017 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three months ended March 31, 2017.

First Quarter 2017 Highlights

  • Sales of $345 million, a 4% increase, reflecting a return to growth following four quarters of decline.
  • GAAP: Net Loss of $4.3 million; Diluted EPS of $(0.14) per share.
  • Non-GAAP: Adjusted Net Income of $12.9 million; Adjusted Diluted EPS of $0.41 per share.
    ◦ Includes negative impact on EPS of approximately $0.10 from foreign currency versus first quarter 2016.
  • Generated $39 million of Cash Flow from Operations and repaid $29 million of debt.
  • Reduced interest rate by 75 bps on $1.0 billion of debt.
  • Company reaffirms 2017 Sales and Adjusted Diluted EPS outlook.

“First quarter results are in-line with our full-year expectations and demonstrate continued progress with our customers as we move our business back to a growth trajectory following a challenging 2016,” said Joseph Dziedzic, Integer’s interim president and chief executive officer. “With the initial phase of our integration efforts nearly behind us, we now turn our focus to optimizing our newly integrated business processes and continuing to serve our customers with differentiated innovation and services. We remain focused on generating strong cash flow to invest for organic growth and to accelerate the pay down of our debt. The first quarter was a good start to the year and supports our reaffirmed 2017 outlook.”

2017 Outlook(a)
(in millions, except per share amounts):

 As Reported Growth Adjusted Growth
Sales $1,390 to $1,430  0% to 3%  $1,390 to $1,430  0% to 3%
Earnings per Diluted Share$1.03 to $1.43  Favorable  $2.70 - $3.10  1% to 16% 
Cash Flow from Operations    ~$150 42%    

(a) Except as described below, further reconciliations by line item to the closest corresponding GAAP financial measures for Adjusted Earnings per Diluted Share, included in our “2017 Outlook” above, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from this non-GAAP financial measure.

(b) Adjusted EPS for 2017 is expected to consist of GAAP Net Income and EPS, excluding items such as intangible amortization ($44 million), IP related litigation costs, and consolidation, acquisition, integration, and asset disposition/write-down charges totaling approximately $77 million. The after-tax impact of these items is estimated to be approximately $53 million, or approximately $1.67 per diluted share.

Summary of First Quarter Financial and Product-Line Results
(dollars in thousands, except per share data)

 Three Months Ended
As Reported
 % Change
 1Q 2017 1Q 2016 Reported  Organic
Medical Sales(a)       
Cardio & Vascular$125,108  $113,671  10% 10%
Cardiac & Neuromodulation103,813  108,533  (4)% (3)%
Advanced Surgical, Orthopedics & Portable Medical  105,146  98,362  7% 8%
Total Medical Sales334,067  320,566  4% 5%
Non-Medical Sales11,346  11,672  (3)%        (3)%
Total Sales$ 345,413  $ 332,238  4% 5%
Net loss$(4,339) $(12,660)      (66)%  
GAAP Diluted EPS$(0.14) $(0.41) (66)%  


        Three Months Ended
 % Change
       1Q 2017 1Q 2016 Reported  Organic

Adjusted EBITDA      $  64,256 $  65,370         (2)% 4%
Adjusted Net Income      $12,913 13,100  (1)%         26%
Adjusted Diluted EPS      $0.41 $0.42  (2)% 24%

(a) During the first quarter of 2017, we revised the method used to present sales by product line in order to align the legacy Greatbatch and Lake Region Medical methodologies.  We believe the revised presentation will provide improved reporting and better transparency into the operational results of our business and markets.  Prior period amounts have been reclassified to conform to the new product line sales reporting presentation.

(b) Refer to Tables A and B at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.

(c) Organic growth for sales excludes the impact of foreign exchange and excludes the results of Nuvectra Corporation (“Nuvectra”) prior to its spin-off on March 14, 2016. Refer to Table C at the end of this release for a reconciliation of these amounts.

(d) Organic growth for Adjusted EBITDA, Adjusted Net Income, and Adjusted Diluted EPS exclude the foreign exchange impact reported in other (income) loss, net. Refer to Table D at the end of this release for a reconciliation of these amounts.

Discussion of Financial Results

  • Sales grew on a reported and organic basis on strength in our Cardio & Vascular and Advanced Surgical, Orthopedics & Portable Medical product-lines. Strengthening demand and growth in our Cardiac & Neuromodulation product-line was muted due to a supply constraint in one of the Company’s fastest growing product offerings.
  • GAAP profitability metrics improved year-over-year primarily due to reduced spending on integration, restructuring, consolidation, and optimization activities, and the spin-off of Nuvectra, partially offset by the impact of unfavorable currency losses.
  • Non-GAAP profitability metrics reflect solid sales growth and the realization of synergies and productivity in operations, partially offset by the inefficiencies of a delayed facility transfer, ramp-up costs for certain customer increased demand versus expectations and delayed sales due to a supply constraint at a customer selected source.
  • The organic non-GAAP profitability metrics exclude the negative effect of foreign exchange losses reported in other (income) loss.

Other Business & Operational Highlights

  • Announced an Executive leadership change and appointed Joseph Dziedzic to serve as Interim President & Chief Executive Officer while the Company actively searches for a permanent replacement.
  • Appointed Gary Haire as Executive Vice President and Chief Financial Officer. Mr. Haire brings nearly 25 years of financial and operational experience, as well as process improvement expertise from several large, multi-national companies.
  • Amended the Company’s senior secured credit agreement lowering the annual interest rate on the Term B Loan facility by 75 basis points.

Conference Call Information
The Company will host a conference call on Monday, May 8, 2017, at 5:00 p.m. EDT to discuss these results.  The scheduled conference call will be webcast live and is accessible through our website at www.integer.net or by dialing (877) 201-0168 (U.S.) or (647) 788-4901 (outside U.S.) and the conference ID is 1815297. The call will be archived on the Company’s website.

About Integer™
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include GreatbatchTM Medical, Lake Region MedicalTM and ElectrochemTM. Additional information is available at www.integer.net.

Notes Regarding Non-GAAP Financial Information
In addition to our results reported in accordance with generally accepted accounting principles (“GAAP”), we provide adjusted net income, adjusted earnings per diluted share, earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA and organic growth rates. Adjusted net income and adjusted earnings per diluted share consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition and integration related charges and expenses, (ii) amortization of intangible assets including inventory step-up amortization, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain litigation expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) gain/loss on cost and equity method investments, (ix) extinguishment of debt charges, (x) the income tax (benefit) related to these adjustments and (xi) certain tax items that are outside the normal provision for the period. Adjusted earnings per diluted share are calculated by dividing adjusted net income by diluted weighted average shares outstanding. Adjusted EBITDA consists of GAAP net income (loss) plus (i) the same adjustments as listed above except for items (x) and (xi), (ii) GAAP stock-based compensation, interest expense, and depreciation, (iii) GAAP provision (benefit) for income taxes and (iv) cash gains received from cost and equity method investments during the period. To calculate organic sales growth rates, which exclude the impact of changes in foreign currency exchange rates, as well as the impact of any acquisitions or divestitures of product lines on sales growth rates, we convert current period sales from local currency to U.S. dollars using the previous periods foreign currency exchange rates and exclude the amount of sales acquired/divested during the period from the current/previous period amounts, respectively. Organic growth rates for Adjusted EBITDA, Adjusted Net Income and Adjusted Diluted EPS exclude the impact of foreign currency exchange gains and losses included in other (income) loss, net. We believe that the presentation of adjusted net income, adjusted diluted earnings per share, EBITDA, adjusted EBITDA, and organic growth rates provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.

Forward-Looking Statements
Some of the statements contained in this press release and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

  • future sales, expenses, and profitability;
  • future development and expected growth of our business and industry;
  • our ability to execute our business model and our business strategy;
  • our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets;
  • our ability to remain in compliance with our debt covenants; and
  • projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this release.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: our high level of indebtedness, our inability to pay principal and interest on this high level of outstanding indebtedness or to remain in compliance with financial and other covenants under our senior secured credit facilities, and the risk that this high level of indebtedness limits our ability to invest in our business and overall financial flexibility; our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost reduction and plant consolidation initiatives; our reliance on third-party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; product field actions or recalls; our inability to successfully consummate and integrate acquisitions, including the acquisition of Lake Region Medical, and to realize synergies and benefits from these acquisitions and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products including system and device products; the timing, progress and ultimate success of pending regulatory actions and approvals; our inability to obtain licenses to key technology; regulatory changes, including health care reform, or consolidation in the healthcare industry; global economic factors including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in our other periodic filings with the SEC. Except as may be required by law, we assume no obligation to update forward-looking statements in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

(in thousands except per share data)
 Three Months Ended
 March 31,
 April 1,
Sales$ 345,413  $ 332,238 
Cost of sales254,187  240,770 
Gross profit91,226  91,468 
Operating expenses:   
Selling, general and administrative expenses (SG&A)  39,499  41,888 
Research, development and engineering costs13,411  17,306 
Other operating expenses (OOE)11,771  21,140 
Total operating expenses64,681  80,334 
Operating income26,545  11,134 
Interest expense28,893  27,617 
Other (income) loss, net1,847  (3,721)
Loss before income taxes(4,195) (12,762)
Income tax provision (benefit)144  (102)
Net loss$(4,339) $(12,660)
Loss per share:   
Basic$(0.14) $(0.41)
Diluted$(0.14) $(0.41)
Weighted average shares outstanding:   
Basic31,016  30,718 
Diluted31,016  30,718 


(in thousands)
  March 31,
  December 30,
Current assets:   
Cash and cash equivalents$54,881  $52,116 
Accounts receivable, net213,610  204,626 
Inventories231,292  225,151 
Refundable income taxes7,679  13,388 
Prepaid expenses and other current assets20,664  22,026 
Total current assets528,126  517,307 
Property, plant and equipment, net371,933  372,042 
Goodwill969,413  967,326 
Other intangible assets, net931,595  940,060 
Deferred income taxes3,978  3,970 
Other assets31,840  31,838 
Total assets$   2,836,885  $2,832,543 
Current liabilities:   
Current portion of long-term debt$34,173  $31,344 
Accounts payable90,713  77,896 
Income taxes payable3,873  3,699 
Accrued expenses75,362  72,281 
Total current liabilities204,121  185,220 
Long-term debt1,668,239  1,698,819 
Deferred income taxes208,542  208,579 
Other long-term liabilities15,325  14,686 
Total liabilities2,096,227  2,107,304 
Stockholders’ equity:   
Common stock31  31 
Additional paid-in capital647,797  637,955 
Treasury stock(4,506) (5,834)
Retained earnings105,050  109,087 
Accumulated other comprehensive loss(7,714) (16,000)
Total stockholders’ equity740,658  725,239 
Total liabilities and stockholders’ equity$2,836,885  $2,832,543 


(in thousands)
 Three Months Ended
  March 31,
 April 1,
Cash flows from operating activities:   
Net loss$ (4,339) $ (12,660)
Adjustments to reconcile net loss to net cash provided by operating activities:     
Depreciation and amortization24,606  22,413 
Debt related charges included in interest expense3,437  1,773 
Stock-based compensation4,669  2,835 
Other non-cash (gains) losses1,499  (3,522)
Deferred income taxes(1,753) (2,445)
Changes in operating assets and liabilities:   
Accounts receivable(8,700) 23,856 
Inventories(5,956) (14,444)
Prepaid expenses and other assets1,853  1,410 
Accounts payable13,146  1,913 
Accrued expenses4,401  7,844 
Income taxes payable5,762  885 
Net cash provided by operating activities38,625  29,858 
Cash flows from investing activities:   
Acquisition of property, plant and equipment(12,328) (18,768)
Purchase of cost and equity method investments(260) (648)
Other investing activities  285 
Net cash used in investing activities(12,588) (19,131)
Cash flows from financing activities:   
Principal payments of long-term debt(79,151) (7,250)
Proceeds from issuance of long-term debt50,000  55,000 
Proceeds from the exercise of stock options7,449   
Payment of debt issuance costs(1,789) (781)
Distribution of cash and cash equivalents to Nuvectra
Purchase of non-controlling interests  (6,818)
Other financing activities  (3,983)
Net cash used in financing activities(23,491) (40,088)
Effect of foreign currency exchange rates on cash and cash equivalents219  1,006 
Net increase (decrease) in cash and cash equivalents2,765  (28,355)
Cash and cash equivalents, beginning of period52,116  82,478 
Cash and cash equivalents, end of period$54,881  $54,123 

Non-GAAP Reconciliations

Table A: Net Income (Loss) and Diluted EPS Reconciliation

 Three Months Ended
 March 31, 2017 April 1, 2016
(in thousands except per share amounts)Pre-Tax Net
 Pre-Tax Net
As reported (GAAP)$ (4,195) $(4,339) $ (0.14) $ (12,762) $ (12,660) $ (0.41)
Amortization of intangibles(a)10,978  7,746  0.24  9,464  6,691  0.21 
IP related litigation (SG&A)(a)(b)377  245  0.01  1,907  1,240  0.04 
Consolidation and optimization expenses (OOE)(a)(c)2,395  1,899  0.06  6,649  5,314  0.17 
Acquisition and integration expenses (OOE)(a)(d)4,820  3,133  0.10  9,965  6,511  0.21 
Asset dispositions, severance and other (OOE)(a)(e)4,556  2,957  0.09  4,526  4,226  0.14 
(Gain) loss on cost and equity method investments, net(a)  398  259  0.01  (1,301) (846) (0.03)
Loss on extinguishment of debt(a)(f)1,559  1,013  0.03       
Nuvectra results prior to spin-off(a)(g)      4,037  2,624  0.08 
Taxes(a)(7,975)     (9,385)    
Adjusted (Non-GAAP)  $12,913  $0.41    $13,100  $0.42 
Adjusted diluted weighted average shares(h)  31,685      31,253   

(a) The difference between pre-tax and net income (loss) amounts is the estimated tax impact related to the respective adjustment. Net income amounts are computed using a 35% U.S. tax rate, and the statutory tax rates in Mexico, Germany, France, Netherlands, Uruguay, Ireland and Switzerland, as adjusted for the existence of net operating losses.  Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.
(b) In 2013, we filed suit against AVX Corporation alleging they were infringing our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, we are excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and a federal jury awarded the Company $37.5 million in damages. To date, no gains have been recognized in connection with this litigation.
(c) During 2017 and 2016, we incurred costs primarily related to the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico, the closure of our Arvada, CO, site and the consolidation of our two Galway, Ireland sites.  In addition, 2017 costs also include expenses related to the closure of our Clarence, NY facility.
(d) Reflects acquisition and integration costs related to the acquisition of Lake Region Medical, which was acquired in October 2015.
(e) Amounts for 2017 include approximately $4.7 million of expense related to our CEO and CFO transitions. Costs for 2016 primarily include legal and professional fees incurred in connection with the spin-off of Nuvectra, which was completed in March 2016.
(f) Represents debt extinguishment charges in connection with pre-payments made on our Term B Loan Facility in the first quarter 2017, which are included in Interest Expense.
(g) Represents the results of Nuvectra prior to its spin-off on March 14, 2016.
(h) The adjusted diluted weighted average shares for the three months ended March 31, 2017 and April 1, 2016 include 669,000 and 535,000, respectively, of potentially dilutive shares not included in the computation of diluted weighted average common shares for GAAP diluted EPS purposes because their effect would have been anti-dilutive given the Company’s net loss in those quarters.


Table B: EBITDA and Adjusted EBITDA Reconciliation

 Three Months Ended
(in thousands)March 31,
 April 1,
Net loss (GAAP)$(4,339) $ (12,660)
Interest expense28,893  27,617 
(Benefit) provision for income taxes144  (102)
Depreciation13,628  12,949 
Amortization10,978  9,464 
EBITDA49,304  37,268 
IP related litigation377  1,907 
Stock-based compensation (excluding OOE)2,406  2,029 
Consolidation and optimization expenses2,395  6,649 
Acquisition and integration expenses4,820  9,965 
Asset dispositions, severance and other4,556  4,526 
Noncash (gain) loss on cost and equity method investments  398  (639)
Nuvectra results prior to spin-off(a)
Adjusted EBITDA (Non-GAAP)$  64,256  $65,370 

(a) Represents the results of Nuvectra prior to its spin-off in March 2016.


Table C: Organic Sales Growth Rate Reconciliation

 Three Months Ended 1Q 2017 vs. 1Q 2016
  Impact of
 Prior to
Sales Growth Rates     
Medical Sales     
Cardio & Vascular10%   10%
Cardiac & Neuromodulation(a)      (4)% 1%       —       (3)%
Advanced Surgical, Orthopedics & Portable Medical(b)  7%          — 1%8%
Total Medical Sales4%  1%5%
Non-Medical Sales(3)%   (3)%
Total Sales4%  1%5%

(a) Cardiac & Neuromodulation sales for 2016 includes $1.2 million relating to Nuvectra prior to its spin-off on March 14, 2016. This amount is excluded from prior year amounts when calculating organic percentage change.
(b) First quarter 2017 sales were negatively impacted by approximately $1.4 million due to foreign currency exchange rate fluctuations, primarily in our AS&O product line.


Table D: Non-GAAP Organic Growth Rate Reconciliation

 Three Months Ended 1Q 2017 vs. 1Q 2016
% ChangeGAAP Impact of
 Impact of
EBITDA32%                 (34)%6%4%
Net Income (Loss)    (66)% 65%       27%      26%
Diluted EPS(66)% 64%26%24%

(a) Represents the impact to our growth rate from our Non-GAAP adjustments. See Tables A and B for further detail on these items.
(b) Represents the impact to our growth rate of the $3.8 million foreign currency exchange loss increase ($3.1 million net of tax, $0.10 per diluted share) reported in other (income) loss, net from the first quarter of 2017 compared to the first quarter of 2016.

Table E: Supplemental Financial Items Affecting Cash Flow
(dollars in millions)   
 2017 Outlook 2016 Actual
Capital Expenditures$50 - $60 $59 
Depreciation and Amortization  $95 - $100 $91 
Stock-Based Compensation~$13 $8 
Working Capital Decrease$10 - $20 $29 
Other Operating Expense$25 - $30 $62 
Adjusted Effective Tax Rate~25% 23% 
Cash Taxes~$10 $7 


Contact Information
Amy Wakeham
VP, Investor Relations
(214) 618-4978

Primary Logo


Source: Integer Holdings Corporation